Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Andrew F. Shorr(Washington Hospital), for the RESPOND Investigators, Antonio Artigas(Instituto de Salud Carlos III), Amy G Leishman(Eli Lilly (United States)), Duncan Wyncoll(Guy's and St Thomas' NHS Foundation Trust), Darell Heiselman(Eli Lilly (United States)), Konrad Reinhart(Charité - Universitätsmedizin Berlin), Bruno François(Inserm), Yajun Emily Zhu(Eli Lilly (United States)), Emmanuelle Mercier(Centre Hospitalier Universitaire de Tours), Burkhard Vangerow(Eli Lilly (United States)), Jean‐Louis Vincent(Université Libre de Bruxelles), Jonathan Janes(Eli Lilly (United States)), Jyrki Tenhunen(Uppsala University)
Cited by 16
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k